With the recent European approval of Lutathera, the first theragnostic radiopharmaceutical of its kind to achieve this milestone, it is no surprise that Advanced Accelerator Applications SA (AAA) is looking more alluring than ever as an acquisition target for a pharma player.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?